For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General & administrative | 927,197 | 755,936.5* | 273,853 | 57,658 |
| Research & development | 2,256,162 | 1,969,662* | 677,474 | - |
| Total operating expenses | 3,183,359 | 2,725,598.5 | 951,327 | 57,658 |
| Loss from operations | -3,183,359 | -2,725,598.5* | -951,327 | -57,658 |
| Interest expense | - | -2,234.5* | 4,090 | 3,091 |
| Other income | 33,131 | 19,865.5* | 1,358 | 403 |
| Net loss | -3,150,228 | -2,703,498.5 | -954,059 | -60,346 |
| Basic EPS | -0.11 | -0.101 | -0.04 | 0 |
| Diluted EPS | -0.11 | -0.101 | -0.04 | 0 |
| Basic Average Shares | 28,344,545 | 26,892,311 | 25,599,673 | 24,000,000 |
| Diluted Average Shares | 28,344,545 | 26,892,311 | 25,599,673 | 24,000,000 |
Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals Inc (CURX)